EMBC EMBECTA CORP

Intuity Medical and embecta Launch Commercial Collaboration, Expanding Access to Self-Management Innovations for People With Diabetes

Intuity Medical and embecta Launch Commercial Collaboration, Expanding Access to Self-Management Innovations for People With Diabetes

FREMONT, Calif. and PARSIPPANY, N.J., Nov. 07, 2022 (GLOBE NEWSWIRE) -- Intuity Medical, Inc. and Embecta Corp. (“embecta”) (NASDAQ: EMBC) today announced they have signed a co-promotional agreement under which embecta sales representatives will be able to promote Intuity Medical’s innovative POGO Automatic® Blood Glucose Monitoring System to healthcare professionals they call on within the U.S., effective immediately.

Both companies are dedicated to improving the lives of people with diabetes. Having spun off from BD (Becton, Dickinson and Company) in April of this year, embecta is one of the world’s largest pure-play diabetes companies and, with a nearly 100-year history of leadership in insulin delivery, well established across the U.S. market. Intuity Medical is a medical technology company focused on the development and commercialization of seamless and intuitive blood glucose monitoring solutions.

“We are excited to partner with an established leader like embecta that has such extensive experience serving people with diabetes,” said George Zamanakos, President and CEO of Intuity Medical. “Working closely with the embecta team will help us expand where we’re able to offer POGO Automatic, giving a new option for simplifying diabetes to millions of people currently relying on conventional blood glucose meters.”

With its 10-test cartridge technology, POGO Automatic is the only FDA-cleared automatic blood glucose monitor (ABGM) that lances, collects blood, and produces a glucose result at the push of one button, ending the need to individually load and then dispose of lancets and test strips. Being able to offer POGO Automatic will expand the innovation and breadth of embecta’s diabetes care offerings.

“The agreement to promote POGO Automatic to healthcare professionals not only enables us to expand our offerings to physicians we call on, but it does so within an innovative new category,” said Tom Blount, Senior Vice President and President, North America, for embecta. “Automatic blood glucose monitoring is transforming this vital aspect of self-management into something truly seamless and simple for people with diabetes.”

About Intuity Medical, Inc.

Intuity Medical, Inc. is a commercial-stage medical technology company focused on developing innovative solutions to improve the health and quality of life of people with diabetes. Headquartered in Fremont, California, the company strives to simplify diabetes management and was founded with the mission of making life with diabetes easier. Intuity Medical’s POGO Automatic® Blood Glucose Monitoring System is the only FDA-cleared automatic blood glucose monitoring system that lances and collects blood in just one step with 10-test cartridge technology, ending the need to individually load lancets and test strips (as required by conventional blood glucose meters). POGO Automatic delivers a much simplified and discreet blood glucose testing experience that is less disruptive to the everyday lives of people with diabetes. To learn more, please visit .

About embecta

embecta, formerly part of BD (Becton, Dickinson and Company), is one of the largest pure-play diabetes care companies in the world, leveraging its nearly 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partnerships and the passion of more than 2,000 employees around the globe. For more information, visit .

CONTACTS

Media (for Intuity Medical):

Jeff Christensen

831-566-0275

Media (for embecta):

Christian Glazar

Sr. Director, Corporate Communications

908-821-6922

 

embecta Investors:

Pravesh Khandelwal

VP, Head of Investor Relations

551-264-6547

A photo accompanying this announcement is available at



EN
07/11/2022

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on EMBECTA CORP

 PRESS RELEASE

embecta to Participate in Investor Events

embecta to Participate in Investor Events PARSIPPANY, N.J., May 27, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global company that is advancing its 100-year legacy in insulin delivery to become a broad-based medical supplies company, today announced that management will participate in the following investor events: 2025 Goldman Sachs Tenth Annual Leveraged Finance and Credit Conference Management will host one-on-one investor meetings on Thursday, May 29, 2025, at Waldorf Astoria Monarch Beach Resort & Club, Dana Point, CA. 2025 Jefferies Global Healthcare Con...

 PRESS RELEASE

embecta to Showcase Phased Approach for Value Creation and Present Lon...

embecta to Showcase Phased Approach for Value Creation and Present Long Range Financial Plan at 2025 Analyst and Investor Day PARSIPPANY, N.J., May 22, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta"; "The Company") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will host its inaugural Analyst and Investor Day today to showcase its phased approach for value creation and present its long range financial plan (“LRP”). "Our Investor Day will provide a comprehensive view of our roadmap for transitioning embecta to growth. We look forward to shari...

 PRESS RELEASE

Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results

Embecta Corp. Reports Second Quarter Fiscal 2025 Financial Results PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. (“embecta” or the "Company") (Nasdaq: EMBC), a global diabetes care company, today reported financial results for the three and six month periods ended March 31, 2025. "This quarter’s financial results were once again slightly ahead of our prior expectations, as our teams executed well, which included driving an acceleration in our free-cash flow generation, thereby allowing us to continue to repay debt and create additional balance sheet flexibility," said ...

 PRESS RELEASE

embecta Announces Quarterly Cash Dividend

embecta Announces Quarterly Cash Dividend PARSIPPANY, N.J., May 09, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Embecta Corp. (“embecta”) (Nasdaq: EMBC) has declared a quarterly cash dividend of $0.15 for each issued and outstanding share of the Company’s common stock. The dividend is payable on June 13, 2025 to stockholders of record at the close of business on May 28, 2025. About embectaembecta is a global diabetes care company that is leveraging its 100-year legacy in insulin delivery to empower people with diabetes to live their best life through innovative solutions, partne...

 PRESS RELEASE

Embecta to host Analyst and Investor Day on May 22, 2025

Embecta to host Analyst and Investor Day on May 22, 2025 PARSIPPANY, N.J., April 28, 2025 (GLOBE NEWSWIRE) -- Embecta Corp. ("embecta") (Nasdaq: EMBC), a global diabetes care company with a 100-year legacy in insulin delivery, will hold an Analyst and Investor Day on May 22, 2025, from 9:00 a.m. to 12:30 p.m. in New York City. Dev Kurdikar, President & Chief Executive Officer, and Jake Elguicze, Chief Financial Officer, will be joined by members of the embecta leadership team to present strategic and business overview, including value creation opportunities, the company’s financial profi...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch